MA56065A - Polythérapie anticancéreuse mettant en oeuvre un composé de sulfonamide et un immunomodulateur - Google Patents

Polythérapie anticancéreuse mettant en oeuvre un composé de sulfonamide et un immunomodulateur

Info

Publication number
MA56065A
MA56065A MA056065A MA56065A MA56065A MA 56065 A MA56065 A MA 56065A MA 056065 A MA056065 A MA 056065A MA 56065 A MA56065 A MA 56065A MA 56065 A MA56065 A MA 56065A
Authority
MA
Morocco
Prior art keywords
polytherapy
immunomodulator
cancer
sulfonamide compound
sulfonamide
Prior art date
Application number
MA056065A
Other languages
English (en)
Inventor
Sayaka TSUKIOKA
Hiroyuki Ueno
Original Assignee
Taiho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiho Pharmaceutical Co Ltd filed Critical Taiho Pharmaceutical Co Ltd
Publication of MA56065A publication Critical patent/MA56065A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
MA056065A 2019-05-29 2020-05-28 Polythérapie anticancéreuse mettant en oeuvre un composé de sulfonamide et un immunomodulateur MA56065A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2019100136 2019-05-29

Publications (1)

Publication Number Publication Date
MA56065A true MA56065A (fr) 2022-04-06

Family

ID=73553795

Family Applications (1)

Application Number Title Priority Date Filing Date
MA056065A MA56065A (fr) 2019-05-29 2020-05-28 Polythérapie anticancéreuse mettant en oeuvre un composé de sulfonamide et un immunomodulateur

Country Status (8)

Country Link
US (1) US20220226291A1 (fr)
EP (1) EP3978017A4 (fr)
JP (1) JP7179174B2 (fr)
KR (1) KR20220015430A (fr)
AU (1) AU2020283299A1 (fr)
MA (1) MA56065A (fr)
TW (1) TWI781405B (fr)
WO (1) WO2020241749A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022187200A1 (fr) * 2021-03-02 2022-09-09 Boundless Bio, Inc. Inhibiteurs de ribonucléotide réductase (rnr) et leurs utilisations
TW202328121A (zh) * 2021-09-17 2023-07-16 美商無界生物公司 環狀磺醯胺核糖核苷酸還原酶(rnr)抑制劑及其用途
WO2023043938A1 (fr) * 2021-09-17 2023-03-23 Boundless Bio, Inc. Inhibiteurs de ribonucléotide réductase (rnr) de sulfamide et leurs utilisations
WO2024059563A1 (fr) * 2022-09-13 2024-03-21 Boundless Bio, Inc. Inhibiteurs de ribonucléotide réductase (rnr) de sulfonamide cyclique et utilisations associées

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI2206517T3 (fi) 2002-07-03 2023-10-19 Ono Pharmaceutical Co Immuunopotentioivia koostumuksia käsittäen anti-PD-L1 -vasta-aineita
AU2015203324B2 (en) * 2009-07-20 2016-07-28 Bristol-Myers Squibb Company Combination of anti-ctla4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases
JOP20200096A1 (ar) * 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
CN106103484B (zh) * 2014-03-14 2021-08-20 诺华股份有限公司 针对lag-3的抗体分子及其用途
DK3466934T3 (da) * 2016-05-31 2024-04-15 Taiho Pharmaceutical Co Ltd Sulfonamidforbindelser eller salt deraf som ribonukleotidreductase-inhibitorer til behandling af kræft
JP7023690B2 (ja) 2017-12-06 2022-02-22 株式会社東芝 道路維持管理システム、道路維持管理方法及びコンピュータプログラム

Also Published As

Publication number Publication date
US20220226291A1 (en) 2022-07-21
JPWO2020241749A1 (fr) 2020-12-03
TW202110442A (zh) 2021-03-16
JP7179174B2 (ja) 2022-11-28
EP3978017A4 (fr) 2023-06-28
EP3978017A1 (fr) 2022-04-06
KR20220015430A (ko) 2022-02-08
WO2020241749A1 (fr) 2020-12-03
AU2020283299A1 (en) 2022-02-03
TWI781405B (zh) 2022-10-21

Similar Documents

Publication Publication Date Title
MA56065A (fr) Polythérapie anticancéreuse mettant en oeuvre un composé de sulfonamide et un immunomodulateur
UA42395S (uk) Футляр
UA44737S (uk) Футляр
MA52090A (fr) Polythérapie
MA54901A (fr) Inhibiteur de 15-pgdh
MA55878A (fr) Ensemble connecteur par coincement-agrafe
CL2020001311S1 (es) Un cabezal de pulverizador portátil
ES2965878T3 (es) Sello mejorado para un pozo
MA53911A (fr) Polythérapie contre le cancer
IT201900020484A1 (it) Strumento di protezione rapida a camme
DK3543954T3 (da) Fremgangsmåde til behandling af en video
MA56057A (fr) Polythérapie
DE102020116468A8 (de) Stereokamera
DK3825501T3 (da) Tætningsbånd
UA43648S (uk) Футляр
JP2020085119A5 (ja) ガスケット
GB201803681D0 (en) A winch fixing
TWI838527B (zh) 加工裝置
JP1714770S (ja) キャリーケース
ES1278739Y (es) Un bolso
JP1728709S (ja) テレプロンプター
TH1902004769S (th) อุปกรณ์สำหรับประทับตรา
IT201900024307A1 (it) Scala a pioli
DK3899027T3 (da) Identifikation af beslægtede par af ligander og en receptorer
TH190857S (th) สร้อบข้อมือ